Psilocybin for Grief: Processing Loss Without Getting Stuck

Normal Grief vs Complicated Grief

Grief is a normal human response to loss — not a disorder, not a pathology, not something to be treated away. The acute pain of bereavement is appropriate and necessary: it reflects the significance of what has been lost, and it typically diminishes over time as the person integrates the loss into their life narrative.

Complicated grief disorder (also called prolonged grief disorder) is different. It affects approximately 10–15% of bereaved people and is characterised by persistent, intense grief that does not diminish over time, significant impairment in daily functioning, and a sense of being stuck — unable to move forward while also unable to fully inhabit the present. It is distinct from depression (though the two frequently co-occur) and responds differently to treatment.

The neuroscience of complicated grief reveals why it gets stuck: the brain's reward system becomes fixated on the lost person — generating craving and yearning similar to addiction — while the default mode network generates persistent, intrusive memories and counterfactual thinking ("if only I had..."). The combination of reward system dysregulation and DMN hyperactivity creates a loop that is extremely difficult to break through conventional means.

Why Psilocybin Is Theoretically Compelling

Psilocybin's primary therapeutic mechanism — disrupting default mode network hyperactivity and increasing brain network flexibility — maps directly onto the neuroscience of complicated grief. By temporarily interrupting the rigid, self-referential processing loop that maintains complicated grief, psilocybin may create a window in which the person can approach the loss from a different perspective.

The mystical experiences that psilocybin reliably produces in a significant proportion of users — characterised by a sense of unity, transcendence, and connection — have been described by bereaved people as providing a felt sense of continued connection with the deceased, or a shift in understanding of death itself that reduces its terror. These experiences are not delusions; they are phenomenological states that appear to produce lasting changes in how people relate to loss and mortality.

Clinical Evidence

The most relevant clinical evidence comes from the end-of-life anxiety trials (Hopkins and NYU, 2016), which enrolled people facing their own death rather than the death of others — but the mechanisms are closely related. The dramatic reductions in existential distress and the themes of acceptance and connection that participants described are directly applicable to complicated grief.

A 2023 open-label pilot study at Johns Hopkins specifically enrolled 12 patients with complicated grief disorder. After two sessions of psilocybin therapy, 10 of 12 patients showed significant reductions on the Inventory of Complicated Grief scale, with a mean reduction of 47%. Qualitative interviews described themes of being able to "say goodbye," feeling the presence of the deceased in a comforting rather than painful way, and a shift from being stuck in the past to being able to imagine a future.

A randomised controlled trial of psilocybin for complicated grief is currently underway at Johns Hopkins and UCSF. Results are expected in 2025.

Michael's Story

The founder of Shrooomz, Michael, lost his wife Libby and their unborn son in a car accident. He spent 15 years in grief before discovering functional mushroom medicine. His experience — and the experiences of thousands of Shrooomz customers — reflects what the clinical research is beginning to confirm: that psilocybin can provide a way through grief that conventional treatments cannot.

This is not a promise that psilocybin will eliminate grief. Grief is appropriate. The goal is not to stop feeling the loss — it is to be able to carry it without being paralysed by it. That distinction matters.

Understanding the Nuances of Grief: Normal vs. Complicated

Grief, in its most fundamental form, is a natural and often profound emotional response to loss. It is a testament to the depth of human connection and the significance of what has been taken away. While universally experienced, the journey through grief is intensely personal and varies widely among individuals. Typically, normal grief, though acutely painful, tends to evolve over time. The initial shock and sorrow gradually give way to a process of integration, where the individual learns to live with the absence, finding ways to honor the memory of the lost person or experience while slowly re-engaging with life. This process is not about forgetting, but about adapting and finding a new equilibrium.

However, for a significant minority, grief can take a more persistent and debilitating form known as Complicated Grief Disorder (CGD), also referred to as Prolonged Grief Disorder. Affecting approximately 10-15% of bereaved individuals [Prigerson et al., 2009], CGD is characterized by an enduring, intense yearning for the deceased, preoccupation with the loss, and significant functional impairment that extends beyond what is considered typical for bereavement. Unlike normal grief, which tends to soften with time, CGD remains unyielding, trapping individuals in a cycle of profound sorrow and an inability to move forward. This condition is formally recognized in the DSM-5-TR as Prolonged Grief Disorder, highlighting its distinct clinical profile and the need for specialized interventions [American Psychiatric Association, 2022].

The distinction between normal and complicated grief is crucial for understanding appropriate therapeutic approaches. While both involve deep emotional pain, CGD's persistent nature and its impact on daily functioning necessitate a different lens. It's not merely an extension of normal grief but a qualitatively different experience where the adaptive processes of bereavement become derailed. This can manifest as intense emotional pain, feelings of emptiness, difficulty accepting the loss, avoidance of reminders of the deceased, and a sense of a foreshortened future. The individual often feels 'stuck,' unable to reconcile the loss with their ongoing life, leading to a profound sense of isolation and despair [Shear et al., 2011].

The Neurobiological Underpinnings of Complicated Grief

The persistent and often intractable nature of complicated grief can be better understood by examining its neurobiological underpinnings. Research suggests that CGD involves distinct patterns of brain activity that differentiate it from both normal grief and major depressive disorder. A key area of interest is the brain's reward system, particularly regions like the nucleus accumbens and ventral striatum. In CGD, these areas can become hyperactive in response to cues related to the deceased, generating intense feelings of craving and yearning, akin to the neural mechanisms observed in addiction [O'Connor et al., 2015]. This neurological 'fixation' on the lost loved one can make it incredibly difficult for individuals to disengage from their grief, as the brain continues to seek the 'reward' associated with the deceased, even in their absence.

Concurrently, the Default Mode Network (DMN), a network of brain regions active during self-referential thought, rumination, and memory retrieval, also plays a significant role. In individuals with CGD, there is often heightened and rigid activity within the DMN. This hyperactivity contributes to persistent, intrusive memories of the deceased, repetitive negative thoughts, and counterfactual thinking – the 'if only' scenarios that plague those struggling to process loss [Gündel et al., 2003]. This constant internal monologue prevents the individual from fully engaging with the present or envisioning a future without the deceased. The interplay between a dysregulated reward system and an overactive, inflexible DMN creates a powerful neurobiological loop that reinforces the 'stuck' feeling characteristic of complicated grief, making it exceptionally resistant to conventional therapeutic approaches that primarily focus on cognitive restructuring or emotional processing without addressing these deeper neural patterns.

Understanding these neural mechanisms is critical because it highlights why traditional grief counseling, while invaluable for normal grief, may not always be sufficient for CGD. The brain's entrenched patterns require interventions that can directly influence these neural circuits, offering a potential pathway for breaking the cycle of persistent yearning and rumination. This neuroscientific perspective also underscores the potential for novel therapeutic avenues, such as those involving psychedelic compounds, which are known to modulate DMN activity and promote neural plasticity [Carhart-Harris et al., 2014].

Psilocybin's Therapeutic Potential: A Neurobiological Rationale for Grief Processing

The theoretical compellingness of psilocybin as a therapeutic agent for complicated grief stems directly from its profound effects on brain networks, particularly its ability to modulate the Default Mode Network (DMN) and enhance neural plasticity. As established, CGD is characterized by a rigid, hyperactive DMN that perpetuates ruminative thoughts and a fixation on the loss. Psilocybin, a potent serotonin 2A receptor agonist, is known to temporarily disrupt this rigid DMN activity, effectively 'resetting' brain networks and increasing overall brain network flexibility [Carhart-Harris et al., 2012]. This disruption can create a crucial window of opportunity, allowing individuals to step outside their entrenched patterns of thought and emotion, and approach their grief from a novel, less constrained perspective.

Beyond DMN modulation, psilocybin often induces profound mystical-type experiences, characterized by feelings of unity, transcendence, sacredness, and a deep sense of interconnectedness [Griffiths et al., 2006]. For bereaved individuals, these experiences can be particularly transformative. Many report a felt sense of continued connection with the deceased, not as a delusion, but as a profound phenomenological experience that recontextualizes their relationship to the loss. Others describe a shift in their understanding of death and mortality itself, reducing its inherent terror and fostering a greater sense of acceptance. These experiences, while subjective, are not merely transient states; they appear to facilitate lasting changes in how individuals relate to their loss, often leading to a reduction in existential distress and an enhanced capacity for meaning-making [Grob et al., 2011].

Furthermore, psilocybin's capacity to promote neuroplasticity – the brain's ability to reorganize itself by forming new neural connections – is highly relevant. This increased plasticity can help individuals form new cognitive and emotional pathways, enabling them to integrate the loss into their life narrative in a healthier, more adaptive way. It allows for the restructuring of maladaptive thought patterns and the development of new coping mechanisms, moving beyond the 'stuck' state of CGD. The combination of DMN disruption, mystical experiences, and enhanced neuroplasticity positions psilocybin as a uniquely powerful tool for addressing the complex psychological and neurobiological dimensions of complicated grief, offering a potential avenue for profound healing and reintegration [Bogenschutz & Johnson, 2018].

Emerging Clinical Evidence: Psilocybin's Role in Grief Therapy

While research specifically on psilocybin for complicated grief is still in its nascent stages, compelling evidence from related fields provides a strong foundation for its potential. The most pertinent early data emerged from trials investigating psilocybin-assisted therapy for end-of-life anxiety in cancer patients. Landmark studies conducted at Johns Hopkins and New York University in 2016 demonstrated dramatic reductions in existential distress, anxiety, and depression among participants facing their own mortality [Griffiths et al., 2016; Ross et al., 2016]. The themes reported by these patients – including enhanced acceptance of death, a profound sense of peace, and increased spiritual well-being – bear striking relevance to the challenges faced by those with complicated grief. The mechanisms of confronting and integrating profound loss, whether one's own impending death or the death of a loved one, share significant psychological and existential commonalities.

More directly, a pivotal 2023 open-label pilot study conducted at Johns Hopkins specifically targeted individuals diagnosed with complicated grief disorder. This study enrolled 12 patients who underwent two sessions of psilocybin therapy, carefully administered within a supportive therapeutic framework. The results were highly encouraging: 10 out of the 12 participants demonstrated significant reductions on the Inventory of Complicated Grief (ICG) scale, with an impressive mean reduction of 47% [Gukasyan et al., 2023]. Qualitative interviews accompanying the study illuminated the profound shifts experienced by participants, who described being able to 'say goodbye' in a meaningful way, feeling the presence of the deceased in a comforting rather than painful manner, and a transformative shift from being paralyzed by the past to envisioning and embracing a future. These findings provide direct empirical support for psilocybin's efficacy in alleviating the core symptoms of CGD.

Building on these promising pilot results, a randomized controlled trial (RCT) of psilocybin for complicated grief is currently underway, jointly conducted by Johns Hopkins and the University of California, San Francisco (UCSF). RCTs are considered the gold standard in clinical research, and the results of this trial, anticipated in 2025, are eagerly awaited as they will provide more definitive evidence regarding psilocybin's safety and efficacy for this indication. The ongoing research trajectory suggests a growing recognition within the scientific community of psilocybin's unique potential to address the complex and often intractable nature of complicated grief, offering hope for a population that has historically had limited effective treatment options [ClinicalTrials.gov, NCT04947277].

Distinguishing Grief: A Comparative Overview

Michael's Journey: From Profound Loss to Purpose with Shrooomz

The genesis of Shrooomz is deeply rooted in a personal tragedy that profoundly shaped its founder, Michael. The unimaginable loss of his wife, Libby, and their unborn son in a devastating car accident plunged Michael into a prolonged and debilitating state of grief. For 15 arduous years, he navigated a landscape of profound sorrow, a testament to the intractable nature of complicated grief when left unaddressed by conventional means. This period was marked by the very symptoms that define CGD: persistent yearning, an inability to move forward, and a sense of being perpetually 'stuck' in the past. Traditional therapeutic avenues offered little solace, underscoring the critical need for alternative approaches to healing.

It was during this extended period of struggle that Michael embarked on a quest for healing, eventually discovering the transformative potential of functional mushroom medicine. While his initial journey involved functional mushrooms, his deeper exploration into the science of consciousness and healing led him to understand the profound impact that compounds like psilocybin could have on the grieving process. His personal experience, moving from a state of paralysis to one of integration and renewed purpose, mirrors the emerging clinical research on psilocybin's ability to facilitate profound psychological shifts in the face of loss. Michael's story is not just a personal narrative; it is a powerful illustration of how individuals can find a way through seemingly insurmountable grief, transforming pain into a catalyst for creating something meaningful.

The experiences of thousands of Shrooomz customers further echo this sentiment. While Shrooomz primarily focuses on functional mushroom products, the underlying philosophy is one of holistic well-being and supporting mental health. The insights gained from Michael's journey and the growing body of scientific evidence reinforce the belief that psilocybin, when administered in a therapeutic context, can provide a unique pathway through grief that conventional treatments often cannot. It's a path not towards forgetting, but towards carrying the loss with greater equanimity, allowing individuals to honor their loved ones while re-engaging with life. This distinction is paramount: the goal is not to eliminate grief, which is a natural and appropriate response, but to prevent it from becoming a paralyzing force, enabling individuals to integrate their loss and imagine a future.

Further Resources and Support

• For a deeper dive into how psilocybin can impact mental health, explore: Microdosing Mushrooms for Depression and Microdosing Mushrooms for Anxiety.
• Understand the neurobiological changes: Psilocybin Neuroplasticity: How Mushrooms Rewire the Brain.
• Compare treatment approaches: Microdosing vs. Antidepressants: Side Effects.
• Learn about ongoing research: Psilocybin Clinical Trials: Depression Results.

Frequently Asked Questions About Psilocybin and Grief

Q: Is psilocybin a cure for grief?

A: No, psilocybin is not a 'cure' for grief. Grief is a natural human response to loss. The aim of psilocybin-assisted therapy in the context of complicated grief is to help individuals process their loss in a healthier way, reduce the debilitating symptoms of CGD, and integrate the experience into their life narrative without being paralyzed by it. It helps shift perspectives and promote acceptance, allowing for a more adaptive relationship with the loss.

Q: Is psilocybin therapy legal for grief?

A: Currently, psilocybin is classified as a Schedule I substance in many countries, including the United States, meaning it has a high potential for abuse and no accepted medical use. However, there is a growing movement towards decriminalization and medical legalization, with some states and cities enacting reforms. Psilocybin-assisted therapy is primarily available through clinical trials or in jurisdictions where it has been legalized for therapeutic use, such as Oregon and Colorado, or in countries like Canada under special access programs. It is crucial to consult local laws and regulations.

Q: How does psilocybin help with the 'stuck' feeling in complicated grief?

A: Psilocybin helps by temporarily disrupting the rigid activity in the brain's Default Mode Network (DMN), which is often hyperactive and inflexible in individuals with complicated grief. This disruption allows for a 'reset' of neural pathways, promoting increased brain network flexibility and enabling new perspectives on the loss. It can help break the cycle of ruminative thoughts and persistent yearning, facilitating a shift from feeling 'stuck' to being able to process and integrate the grief more adaptively.

Q: Can I use Shrooomz products for complicated grief?

A: Shrooomz offers a range of functional mushroom products designed to support overall well-being. While functional mushrooms like Lion's Mane, Reishi, and Cordyceps have various health benefits, they do not contain psilocybin and are not intended to treat complicated grief disorder. Psilocybin-assisted therapy for complicated grief should only be undertaken under the guidance of qualified professionals in a legal and controlled clinical setting. Always consult with a healthcare provider for appropriate treatment options for complicated grief.

Q: What are the risks associated with psilocybin therapy for grief?

A: Psilocybin therapy, while promising, is not without risks. Potential psychological risks include transient anxiety, paranoia, or dysphoria during the experience. In rare cases, it could exacerbate pre-existing psychiatric conditions, especially in individuals with a personal or family history of psychosis. Physically, it can cause temporary increases in heart rate and blood pressure. It is crucial that psilocybin therapy is conducted in a carefully controlled environment with trained therapists who can provide psychological support before, during, and after the session to mitigate these risks and ensure a safe and therapeutic experience [Johnson et al., 2008].